From: Identifying drug-pathway association pairs based on L2,1-integrative penalized matrix decomposition
Drug | KEGG pathway | L 2, 1-iPaD | iPaD | Validated? |
---|---|---|---|---|
Hydroxyurea | Neuroactive ligand-receptor interation | 0 | NAN | No |
Rebeccamycin | T cell receptor signaling pathway | 4.12E-16 | 4.65E-10 | Yes |
Tiazofurin | Cell cycle | 8.19E-11 | 7.54E-07 | Yes |
Selenazofurin | Cell cycle | 1.75E-10 | 2.78E-07 | Yes |
Mycophenolic Acid | Cell cycle | 2.61E-10 | 2.52E-06 | No |
Lucanthone | Tight junction | 1.04E-08 | 4.31E-06 | Yes |
Tanespimycin | Jak-STAT signaling pathway | 9.95E-07 | 2.67E-04 | No |
Primaquine | Natural killer cell mediated cytotoxicity | 1.14E-06 | 2.69E-04 | No |
Aminoglutethi-mide | Primary immunodeficiency | 1.30E-06 | 1.16E-04 | No |
Geldanamycin | Gap junction | 7.89E-06 | 1.87E-04 | No |
Diallyl Disulfide | Acute myeloid leukemia | 8.13E-06 | 8.41E-05 | No |
Carmustine | Cell cycle | 8.68E-06 | 4.58E-04 | No |
Lomustine | Tight junction | 1.06E-05 | 2.64E-04 | Yes |
Bleomycin | Focal adhesion | 1.17E-05 | 4.56E-04 | No |
Vitamin K 3 | Metabolism of xenobiotics by cytochrome P450 | 2.22E-05 | 2.71E-04 | No |
Melphalan | T cell receptor signaling pathway | 2.64E-05 | 6.16E-04 | Yes |
Tegafur | Gap junction | 6.73E-05 | 5.60E-04 | No |
Chloroquine Phosphate | Tight junction | 7.12E-05 | 8.76E-04 | Yes |
Aclacinomyci- ns | One carbon pool by folate | 1.03E-04 | 5.41E-04 | No |
Tamoxifen | Pyrimidine metabolism | 1.12E-04 | 1.92E-03 | No |